ReviewFrontiers in oncology2026
Non-small cell lung cancer research: advances and persistent challenges.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic Repression ofBiomolecules & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, prompting significant advancements in therapeutic and precision medicine. Recent innovations include antibody-drug conjugates (ADCs) such as TROP-2-targeting agents and HER3-DXd, which show promising efficacy in refractory disease. Next-generation tyrosine kinase inhibitors (TKIs), including lorlatinib, tepotinib, and glecirasib, have shown improved outcomes for patients with oncogene-driven NSCLC. Immunotherapy continues to evolve, with novel therapeutic targets and metabolic modulation strategies expanding its potential. Emerging diagnostic tools, such as liquid biopsy and artificial intelligence (AI)-based histopathology, are enhancing prognostic accuracy and enabling more personalized treatment approaches. Despite these advancements, significant challenges persist. Acquired resistance mechanisms and bypass pathways continue to undermine long-term therapeutic efficacy. Limitations in biomarker utility, including the imperfect predictive value of PD-L1and the lack of validation for ctDNA, STK11, and KEAP1, complicate treatment decision-making. While comprehensive genomic profiling (CGP) has expanded the detection of actionable targets, barriers such as accessibility, reimbursement issues, and workflow integration remain, with only 11-34% of eligible patients receiving matched therapies. Additionally, critical data gaps exist for elderly patients and rare subtypes such as hepatoid adenocarcinoma. Future efforts must prioritize overcoming resistance through combination strategies and ADCs, validating biomarkers using AI and ctDNA, streamlining CGP implementation, and addressing the unique needs of special populations. Bridging these biological and systemic challenges is essential for improving survival outcomes and ensuring equitable benefits for all NSCLC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.